Abstract. Artemether-lumefantrine is a new fixed antimalarial combination effective against multidrug-resistant falciparum malaria. A prospective electrocardiographic study was conducted in 150 patients receiving artemetherlumefantrine and 50 treated with artesunate-mefloquine. There was no evidence for clinically significant changes in the electrocardiographic intervals and in particular no relationship between plasma concentrations of lumefantrine and QTc prolongation. Artemether-lumefantrine does not have significant cardiac effects at therapeutic doses.
Artemether and lumefantrine (benflumetol) is a new combination effective against multidrug-resistant falciparum malaria. Lumefantrine is a racemic fluorene derivative with the chemical name 2-dibutylamino-1-[2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]-ethanol. It conforms structurally, to the aryl-amino alcohol group of antimalarials including quinine, mefloquine, and halofantrine. Other antimalarials notably quinine, and to a greater extent quinidine and halofantrine, are known to prolong ventricular repolarization reflected in prolongation of the electrocardiographic QTc-interval at therapeutic dosages, 1,2 and halofantrine has been associated with sudden death. 2, 3 Artemether is a methyl-ether derivative of dihydroartemisinin, derived from artemisinin (Qinghaosu). Artemether, and the closely related compound arteether, given in high doses by intramuscular injection prolong the QTc-interval in rats and dogs 4 , which has given rise to concern that similar effects could occur in clinical use. However, there is no evidence from large prospective clinical studies of any cardiotoxicity with this compound in humans. 5, 6 Artemether-lumefantrine has usually been given in a 4-dose regimen comprising a total of 320 mg of artemether and 1,920 mg of lumefantrine for adults. In Thailand, 2 studies were conducted with a 6-dose regimen that gave higher cure rates than the 4-dose regimen and was equally well tolerated. 7, 8 These large dose-optimizing studies with higher dose regimens provided the opportunity to conduct detailed electrocardiographic studies and to relate any changes observed to the plasma concentrations of lumefantrine.
METHODS
Electrocardiographic monitoring and measurement of plasma lumefantrine concentrations were conducted in a randomized, 2-center trial conducted in adults and children more than 2 years old presenting with uncomplicated falciparum malaria in Bangkok, involving predominantly Thai and Mon subjects, or in a camp for displaced persons (predominantly Karen) living on the western border of Thailand. 8 After giving informed consent, patients were allocated randomly to receive either artemether-lumefantrine, adult dose: 4 tablets twice a day for 3 days (each tablet contains 20 mg of artemether and 120 mg of lumefantrine) or the current standard combination treatment: artesunate in a single daily dose of 4 mg/kg/day for 3 days plus mefloquine in a split dose, i.e., 15 mg/kg on day 2 and 10 mg/kg on day 3. 9 Blood microscopy was performed daily until 2 negative results were obtained, then weekly. Axillary temperature was measured daily until day 3. These studies were approved by the Ethical Committee of the Faculty of Tropical Medicine, Mahidol University, and the Karen Refugee Committee.
Five venous blood samples were withdrawn from all patients treated with artemether-lumefantrine. To optimize information, sampling times were chosen according to 1 of 2 randomized schedules: before dose 2 (or 3), before dose 4 (or 5), before dose 6, 8-16 hours after dose 6, and at day 7 (the schedules were only different for the first 2 sampling times). At each time point 4 ml of blood was collected into heparinized tubes and centrifuged at 1,000 rpm for 15 min before freezing at Ϫ70ЊC. Plasma concentrations of lumefantrine were measured using high-performance liquid chromatography with UV detection. The limit of quantitation was set to 100 ng/ml (interassay coefficient of variation Ͻ10%). 10 Electrocardiograms (ECGs). Electrocardiographic monitoring (Autocardiner FCP-2155; Fukuda Denshi Co., Ltd., Tokyo Japan) was performed at baseline, day 7, and day 28 for all patients. In the group treated with artemetherlumefantrine, an additional 4 ECGs were performed within the first week at the same time as blood sampling for antimalarial drug levels. For patients receiving artesunate-mefloquine, an additional 3 ECGs were taken about 1 hr after the first and second dose of mefloquine, respectively, on day 1 and day 2, and again about 24 hr after the second dose of mefloquine.
Electrocardiographic intervals were measured automatically by the machine and their absolute and percentage changes from baseline were summarized. The QT interval and heart rate were used to calculate the QTc interval using Bazett's formula: QTc ϭ QT/͙(RR).
The QTc interval as the response variable was compared between treatments. Times of ECG recordings were similar but not identical for all subjects; thus, they were classified as ECG numbers 1 to 6 (days 0 [after baseline], 1, 2, 3, 7, and 28). A statistical model was fitted including QTc values at baseline (day 0), age, heart rate, center, and ECG number as secondary covariates and treatment as the main effect. To account for the grouping of QTc values within an individual, patient effect was added to the model as a random effect. Changes in mean estimates of QTc at different time points were considered in reference to the mean estimate of day 28 (ECG number 6), when malaria effects were expected to have disappeared. Within the group treated with artemetherlumefantrine, a similar model was fitted except that the plasma lumefantrine concentration was used as the main effect.
No plasma samples were taken at day 28. There have been extensive recent studies of the pharmacokinetic properties of lumefantrine in more than 500 patients with malaria. Lumefantrine has a terminal elimination half-life of 3-4 days.
11
Thus, at day 28 lumefantrine concentrations in plasma are below the level of reliable detection (Ͻ50 ng/ml or Ͻ2% of peak values). Plasma lumefantrine concentrations at this time were therefore set equal to zero. To eliminate time effects, the relationship of the plasma lumefantrine concentration to the QTc interval at ECG number 4 (when lumefantrine levels were near maximum) was also investigated. The procedure MIXED of the statistical package SAS, version 6.12 (SAS Institute Inc., Cary, NC) was used for these analyses.
RESULTS
Full clinical details of this study will be reported elsewhere. 8 None of the patients had a history of arrhythmias or syncopal episodes. Clinical baseline characteristics were similar in both groups ( Table 1) . The median (range) age and body weight were 22 years (2-63) and 50 kg (8-81), respectively. There were no significant adverse cardiovascular episodes.
Electrocardiographic findings. Electrocardiographic data were available for 199 patients, (150 treated with artemetherlumefantrine and 49 treated with artesunate-mefloquine) including 34 children Յ12 years old. The median (range) heart rate at baseline was 89 (54-162) bpm. This decreased during the course of the treatment. The median (range) baseline PR interval was 138 (99-247) msec and the median (range) QRS interval was 92 (30-116) msec. Both remained unchanged following treatment. At baseline, the median (range) QTc was 412 ms (354-484). Excluding baseline measurements, 1,085 QTc machine-read measurements were available, 859 from patients treated with artemether-lumefantrine and 226 from patients treated with artesunate-mefloquine. A total of 711 observations were available for the evaluation of the effect of the plasma lumefantrine concentration on QTc interval, in which there were detectable plasma lumefantrine concentrations. The day 28 intervals were considered to represent the normal values for the individual since plasma lumefantrine concentrations are below the level of detection (Ͻ50 ng/ml) by this time; 11 setting these values to zero drug effect resulted in an additional 128 observations; a total of 839 observations for lumefantrine.
There was no significant difference in pretreatment QTc values between the 2 drug groups. Fitting the mixed effect model, QTc at baseline, age, heart rate, center, and ECG number were each found to have statistically significant effects on the QTc interval. There was no evidence of a treatment effect on the QTc interval ( Table 2 ). The greatest increase in QTc during treatment, compared with day 28, was estimated to be 8 msec (P Ͻ 0.0001) at the fourth ECG, approximately 67 hr after the start of the treatment. To examine the QTc patterns over time for each treatment, a sep- arate QTc evaluation was carried out for each treatment group. The greatest increase in QTc, compared with that of day 28, was 7.1 msec (P Ͻ 0.0001) for artemether-lumefantrine and 11.6 msec (P ϭ 0.001) for artesunate-mefloquine, both on ECG number 4, i.e., day 3.
In the artemether-lumefantrine group, the relationship between the QTc interval and plasma lumefantrine concentrations (839 observations) was investigated (Figure 1) . The likelihood ratio test showed that the best fit was achieved with a model taking into account the ECG number (i.e., time effect) rather than the plasma lumefantrine concentration. To exclude this time effect, the subset of QTc data collected at the fourth ECG were evaluated to examine again possible differences between patients as a result of differences in plasma lumefantrine concentrations. Again baseline QTc and heart rate had statistically significant effects on the QTc interval, while plasma lumefantrine concentration had none (Table 3) , despite the wide range of lumefantrine levels (442-30,605 ng/ml, median ϭ 5,996 ng/ml, n ϭ 141).
Only 2 patients showed an increase of more than 25% in the machine-read QTc interval compared with their baseline values: 1 patient receiving artemether-lumefantrine had an increase from 355 msec to 453 msec (at 38 hr) and 1 patient receiving artesunate-mefloquine had an increase from 397 ms to 527 ms (at 47 hr); the only patient in the series with a QTc value Ͼ500 msec. The manual readings made at these times by an independent cardiologist were 376 msec in the first case and 351 msec in the second case, indicating machine errors. Manually read ECGs were therefore made for all patients (n ϭ 41) with QTc increases compared with baseline values greater than 30 msec. Analysis of approximately 250 ECGs showed that machine-calculated QTc values were generally higher than manually read values. 12 The difference was greater at high QTc values, e.g., for machine readings greater than 450 msec, the manually read values were lower by an average of 25 msec (n ϭ 49).
DISCUSSION
There has been natural concern over the cardiotoxic potential of newly introduced antimalarial drugs since the unexpected discovery of the marked effects of halofantrine on ventricular repolarization, well after it had been introduced in clinical practice. 2, 3, 13, 14 Electrocardiogram QT prolongation is a well known risk factor for proarrhythmic events, including sudden death. Lumefantrine is an aryl-amino alcohol antimalarial with some structural similarities to halofantrine. It is also, like halofantrine, lipophilic and hydrophobic, with very variable oral bioavailability leading to considerable inter-individual variability in plasma concentrations. However, unlike halofantrine, it proved to have no detectable cardiac effects over a wide range of plasma concentrations. In this study, there was no change in the electrocardiographic PR and QRS intervals after starting antimalarial treatment. Generally, small changes in QTc interval were noted, but they were similar to those reported in patients with malaria treated with other antimalarial drugs (and much less than those recorded after treatment with drugs known to prolong the QT interval), and they were unrelated to the plasma concentrations of lumefantrine. Several factors including age, heart rate, recovery from malaria, and, interestingly, study site (perhaps reflecting ethnic or nutritional differences between Karen and Thai subjects) were related to QT intervals, but drug levels were not. If lumefantrine had any significant effects on cardiac conduction or repolarization, then there should have been a relationship between concentration and effect, but none was found in this large and detailed study (Figure 1) . Clear concentration-effect relationships are evident with halofantrine and quinidine, which have the greatest repolarization effects in this class of antimalarials, 1,2 and can also be demonstrated for quinine (the L-diastereomer of quinidine), which has less effect on the QT interval. 1 There has been debate recently whether malaria itself affects ventricular repolarization. Small but significant differences have been observed in the QT interval corrected by Bazett's formula between acute malaria and convalescence. 15 These are associated with a decrease in heart rate associated with defervescence. Dividing the QT interval by the square root of the R-R interval does not correct adequately for changes in heart rate since heart rate and QT/͙RR remain significantly correlated. 16 Thus, the apparent malaria effect on ventricular repolarization may simply reflect heart rate changes. In any case, the effects are very small. In this study, there was a small but statistically significant difference in QTc interval at the third day (after end of treatment), but this was similar for the 2 drugs, suggesting that it was related to recovery from malaria and not the antimalarial drugs themselves. Mefloquine has also been investigated in detail 17 and is considered not to have clinically important effects on ventricular repolarization. Patients with pre-existing repolarization abnormalities may be more vulnerable to factors that prolong the QT interval. In this series, there was no relationship between baseline QTc interval and the fractional increase. Overall, these data provide strong evidence against a systematic effect of therapeutic doses of lumefantrine on cardiac conduction or repolarization.
